Effect of photodynamic therapy on urinary bladder function: an experimental study with rats

Area of Science:

• Urology
• Oncology
• Biomedical Engineering

Background:

• Photodynamic therapy (PDT) utilizes photosensitizing drugs and light to induce localized necrosis.
• Current PDT in urology faces limitations due to laser dosimetry and bladder function complications.
• Aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) is a photosensitizer investigated for PDT.

Purpose of the Study:

• To evaluate the safety and functional impact of photodynamic therapy on rat urinary bladders.
• To determine optimal light dosimetry for ALA-induced PDT in bladder tissue.
• To assess the transient nature of functional bladder changes post-PDT.

Main Methods:

• Rats received intravenous ALA, followed by intravesical laser radiation (20, 40, or 80 J/cm²) 4 hours later.
• Control group received radiation without ALA.
• Bladder capacity and pressure were assessed using cystometry before and at multiple time points after PDT.

Main Results:

• Light doses of 20 and 40 J/cm² with ALA did not reduce bladder capacity.
• A light dose of 80 J/cm² resulted in up to 50% capacity reduction at 3 weeks.
• Control animals without ALA showed significant capacity reduction (over 66%) at 3 weeks.
• ALA with 20 and 40 J/cm² light induced transient functional changes, resolving by day 1.

Conclusions:

• Optimized dosing of ALA and light energy can minimize transient functional impairment of the urinary bladder.
• PDT demonstrates potential as a safe therapeutic option for superficial bladder cancer.
• Careful light dosimetry is crucial for managing PDT-related side effects in bladder treatment.